Literature DB >> 9521101

Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling.

T Piironen1, B O Villoutreix, C Becker, K Hollingsworth, M Vihinen, D Bridon, X Qiu, J Rapp, B Dowell, T Lövgren, K Pettersson, H Lilja.   

Abstract

Prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2), produced essentially by the prostate gland, are 237-amino acid monomeric proteins, with 79% identity in primary structure. Twenty-five anti-PSA monoclonal antibodies (Mabs) were studied for binding to a large array of synthetic linear peptides selected from computer models of PSA and hK2, as well as to biotinylated peptides covering the entire PSA sequence. Sixteen of the Mabs were bound to linear peptides forming four independent binding regions (I-IV). Binding region I was localized to amino acid residues 1-13 (identical sequence for PSA and hK2), II (a and b) was localized to residues 53-64, III (a and b) was localized to residues 80-91 (= kallikrein loop), and IV was localized to residues 151-164. Mabs binding to regions I and IIa were reactive with free PSA, PSA-ACT complex, and with hK2; Mabs binding to regions IIb, IIIa, and IV were reactive with free PSA and PSA-ACT complex, but unreactive with hK2; Mabs binding to region IIIb detected free PSA only. All Mabs tested (n = 7) specific for free PSA reacted with kallikrein loop (binding region IIIb). The presence of Mabs interacting with binding region I did not inhibit the catalytic activity of PSA, whereas Mabs interacting with other binding regions inhibited the catalysis. Theoretical model structures of PSA, hK2, and the PSA-ACT complex were combined with the presented data to suggest an overall orientation of PSA with regard to ACT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521101      PMCID: PMC2143911          DOI: 10.1002/pro.5560070205

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  33 in total

1.  Primary structure of a human glandular kallikrein gene.

Authors:  L J Schedlich; B H Bennetts; B J Morris
Journal:  DNA       Date:  1987-10

2.  Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins.

Authors:  M Wilczynska; M Fa; J Karolin; P I Ohlsson; L B Johansson; T Ny
Journal:  Nat Struct Biol       Date:  1997-05

3.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

4.  Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma.

Authors:  D Deperthes; P Chapdelaine; R R Tremblay; C Brunet; J Berton; J Hébert; C Lazure; J Y Dubé
Journal:  Biochim Biophys Acta       Date:  1995-12-14

5.  Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum.

Authors:  T Piironen; J Lövgren; M Karp; R Eerola; A Lundwall; B Dowell; T Lövgren; H Lilja; K Pettersson
Journal:  Clin Chem       Date:  1996-07       Impact factor: 8.327

6.  Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.

Authors:  T Björk; T Piironen; K Pettersson; T Lövgren; U H Stenman; J E Oesterling; P A Abrahamsson; H Lilja
Journal:  Urology       Date:  1996-12       Impact factor: 2.649

7.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity.

Authors:  J Lövgren; T Piironen; C Overmo; B Dowell; M Karp; K Pettersson; H Lilja; A Lundwall
Journal:  Biochem Biophys Res Commun       Date:  1995-08-24       Impact factor: 3.575

9.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.

Authors:  J E Oesterling; S J Jacobsen; G G Klee; K Pettersson; T Piironen; P A Abrahamsson; U H Stenman; B Dowell; T Lövgren; H Lilja
Journal:  J Urol       Date:  1995-09       Impact factor: 7.450

10.  Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.

Authors:  B O Villoutreix; H Lilja; K Pettersson; T Lövgren; O Teleman
Journal:  Protein Sci       Date:  1996-05       Impact factor: 6.725

View more
  4 in total

1.  The epitope space of the human proteome.

Authors:  Lisa Berglund; Jorge Andrade; Jacob Odeberg; Mathias Uhlén
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

2.  Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Authors:  Susan Evans-Axelsson; David Ulmert; Anders Örbom; Pernilla Peterson; Olle Nilsson; Johan Wennerberg; Joanna Strand; Karin Wingårdh; Tomas Olsson; Zandra Hagman; Vladimir Tolmachev; Anders Bjartell; Hans Lilja; Sven-Erik Strand
Journal:  Cancer Biother Radiopharm       Date:  2012-04-10       Impact factor: 3.099

3.  Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.

Authors:  David Ulmert; Michael J Evans; Jason P Holland; Samuel L Rice; John Wongvipat; Kim Pettersson; Per-Anders Abrahamsson; Peter T Scardino; Steven M Larson; Hans Lilja; Jason S Lewis; Charles L Sawyers
Journal:  Cancer Discov       Date:  2012-03-31       Impact factor: 39.397

4.  Three genes expressing Kunitz domains in the epididymis are related to genes of WFDC-type protease inhibitors and semen coagulum proteins in spite of lacking similarity between their protein products.

Authors:  Adam Clauss; Margareta Persson; Hans Lilja; Åke Lundwall
Journal:  BMC Biochem       Date:  2011-10-11       Impact factor: 4.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.